← Leaderboards
Amer Aziz Beg
Columbia Univ New York Morningside
$7,960,036
Attributed
$9,462,886
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $842.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,462,886 · 7
By mechanism
R01$8,999,511 · 6
R21$463,375 · 1
Top collaborators
- Xue-Zhong Yu5 shared
- Scott J Antonia4 shared
Most similar at Columbia Univ New York Morningside
Same institution · by research overlap
- Neel H Shah$2,946,450
- Andrea Norcini Pala$2,229,559
- Sanket Rane$1,477,619
- Christoph Juchem$2,983,652
- Tal Danino$10,808,082
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseT-LymphocyteNeoplastic CellTumorImmunotherapyCell TypeCell PhysiologyGenesMalignant NeoplasmsPathway InteractionsNon-Small-Cell Lung CarcinomaImmuneCellsTumor MicroenvironmentMalignant Neoplasm Of LungCancer PatientSignal TransductionMediatingInflammatoryT-Cell ActivationLeadIn VivoLungImmune Response
Grant awards (28)
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients$460,204
R01 · FY2025 · CA · contact PI
Defining impact of in situ activation of CD40 and type 1 interferon signaling on theTME and systemic T cell immunity in murine models and cancer patients$460,204
R01 · FY2024 · CA · contact PI
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade$393,450
R01 · FY2021 · CA · contact PI
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade$393,450
R01 · FY2020 · CA · contact PI
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade$381,646
R01 · FY2019 · CA · contact PI
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade$393,450
R01 · FY2018 · CA · contact PI
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$259,646
R01 · FY2018 · CA · contact PI
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$189,200
R01 · FY2018 · CA
Augmenting T cell trafficking and functionality through novel combinations of epigenetic agents and PD-1 blockade$393,450
R01 · FY2017 · CA · contact PI
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$259,646
R01 · FY2017 · CA
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$189,200
R01 · FY2017 · CA
Targeting the adenosine A2A receptor immune checkpoint in lung cancer patients$321,654
R01 · FY2016 · CA
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$413,325
R01 · FY2014 · AI · contact PI
Modulating the immune response to adenovirus vectors through NF-kB/IRF3 activatio$210,625
R21 · FY2014 · AI · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$388,526
R01 · FY2013 · AI · contact PI
Modulating the immune response to adenovirus vectors through NF-kB/IRF3 activatio$252,750
R21 · FY2013 · AI · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$413,325
R01 · FY2012 · AI · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$413,325
R01 · FY2011 · AI · contact PI
Elucidating the Function of PKC-theta in Alloreactivity and GVHD$417,500
R01 · FY2010 · AI · contact PI
Mechanisms of co-stimulatory molecule expression in DCs$341,139
R01 · FY2009 · AI · contact PI
Mechanisms of co-stimulatory molecule expression in DCs$341,139
R01 · FY2008 · AI · contact PI
Mechanisms of co-stimulatory molecule expression in DCs$347,746
R01 · FY2007 · AI · contact PI
Mechanisms of co-stimulatory molecule expression in DCs$358,132
R01 · FY2006 · AI · contact PI
Mechanisms of co-stimulatory molecule expression in DCs$299,477
R01 · FY2005 · AI
Regulation of lymphocyte survival by NF-kB proteins$289,335
R01 · FY2004 · CA
Regulation of lymphocyte survival by NF-kB proteins$288,769
R01 · FY2003 · CA
Regulation of lymphocyte survival by NF-kB proteins$288,204
R01 · FY2002 · CA
NF-KB PROTEINS AND CELL SURVIVAL$304,369
R01 · FY2000 · CA